
Sign up to save your podcasts
Or


Dr Bryant England discusses the use of TNF-inhibitor versus non-TNF inhibitor biological or targeted synthetic DMARDs for treatment of rheumatoid arthritis-associated ILD, and the effects on survival and respiratory hospitalisation outcomes.
Read the full article:
https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(24)00265-0/fulltext?dgcid=buzzsprout_icw_podcast_generic_lanrhe
Continue this conversation on social!
Follow us today at...
https://thelancet.bsky.social/
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv
By The Lancet GroupDr Bryant England discusses the use of TNF-inhibitor versus non-TNF inhibitor biological or targeted synthetic DMARDs for treatment of rheumatoid arthritis-associated ILD, and the effects on survival and respiratory hospitalisation outcomes.
Read the full article:
https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(24)00265-0/fulltext?dgcid=buzzsprout_icw_podcast_generic_lanrhe
Continue this conversation on social!
Follow us today at...
https://thelancet.bsky.social/
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv

127 Listeners

112,333 Listeners

56,404 Listeners

23 Listeners

114 Listeners

121 Listeners

70 Listeners

22 Listeners

0 Listeners

0 Listeners

182 Listeners

2 Listeners

1 Listeners

0 Listeners

1 Listeners

0 Listeners

0 Listeners

1 Listeners

1 Listeners

0 Listeners

1 Listeners

0 Listeners

0 Listeners

0 Listeners

19 Listeners

6 Listeners

0 Listeners

0 Listeners

0 Listeners